Nevirapine Lp Sandoz

Nevirapine, the active ingredient in Nevirapine Lp Sandoz, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral tablet for systemic use. It is employed in the treatment of HIV‑1 infection, helping to suppress viral replication in adults and children.

GNH USA supplies Nevirapine Lp Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering reliable global distribution. Our network ensures timely delivery across multiple continents.

Nevirapine is an NNRTI used in antiretroviral therapy to target HIV‑1 replication.

- HIV‑1 infection (adults): Reduces plasma viral load and improves CD4+ cell counts when used in combination regimens. - HIV‑1 infection (children): Provides effective viral suppression as part of pediatric antiretroviral therapy. - Treatment‑experienced HIV‑1 infection: Offers an alternative option for patients with resistance to other drug classes.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: Mild to moderate skin eruptions that may be pruritic. - Nausea: Transient gastrointestinal discomfort. - Fatigue: Generalized tiredness without specific cause. - Headache: Mild to moderate intensity.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: Severe mucocutaneous reaction requiring immediate discontinuation. - Hepatotoxicity: Elevated liver enzymes or clinical hepatitis. - Hypersensitivity reactions: Including fever, eosinophilia, and systemic involvement.

Nevirapine requires careful monitoring to mitigate potential risks.

- Liver monitoring: Perform baseline and periodic liver function tests due to risk of hepatotoxicity. - Rash surveillance: Observe for skin reactions and discontinue if severe rash develops. - Drug interactions: Avoid concomitant use with potent CYP3A4 inducers such as rifampicin. - Hepatitis co‑infection: Use with caution in patients with hepatitis B or C. - Store at ambient temperature below 25°C: Keep in original container, protect from moisture.

Nevirapine interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Rifampicin: Strong CYP3A4 induction markedly reduces nevirapine exposure. - St. John’s wort: Herbal CYP3A4 inducer that can lower plasma concentrations. - Efavirenz: Co‑administration may increase toxicity due to overlapping metabolic pathways.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): May increase nevirapine levels, requiring dose adjustment. - Azole antifungals (e.g., ketoconazole): Can raise nevirapine concentrations and necessitate monitoring.